Researchers create 'leukemia in a dish' to better study it

October 8, 2015
A Wright's stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikipedia

Scientists engineered stem cells to better understand the mechanisms behind a form of leukemia caused by changes in a key gene, according to a study led by Mount Sinai researchers and published online today in the journal Cell Reports.

Past work had established that inherited changes in the DNA code for the gene PTPN11 cause Noonan syndrome, a genetic disease that comes with a high risk for the blood cancer called juvenile myelomonocytic leukemia (JMML). The mechanisms behind the disease, and what influences its severity, were unknown going into the current study.

In addition, the only current treatment for JMML, a bone marrow transplant to replace the that become , is effective in only 50 percent of patients. This has further spurred efforts to understand related disease mechanisms as a step toward designing better treatments.

"By studying an inherited human cancer syndrome, our study clarified early events in the development of one kind of leukemia," said corresponding study author Bruce D. Gelb, MD, Gogel Family Chair and Director of The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai. "More than just creating a model of a disease, we were able to prove that mechanisms seen in our model also happen in the bone marrow of people with this kind of leukemia. The work also provided new targets for the field to develop new drugs against in JMML."

To better understand diseases with a genetic component, a popular approach is to take skin cells from patients with a disease and use enzymes to coax the cells back along the differentiation pathway to become induced or iPSCs. Such cells can then be programmed to mature into cells, including hematopoietic (blood) cells, which re-create a specific version of each person's genetic disease in a petri dish for study.

In the current publication, the study authors report that produced from induced with PTPN11 mutations known to cause JMML indeed act like cells seen in these patients. Researchers found that "gain of function" genetic changes that happen to increase this protein's expression were enough to cause leukemia-related changes in cells.

"Going into the current study, experts in the field had tended to lump all forms of JMML together, but the new study was able to isolate biological changes specific to hematopoietic cells with PTPN11 mutations, which causes more severe JMML," said Dr. Gelb. "These findings provide a toe-hold in efforts to design specific treatments for this form of the disease."

iPSCs used to model cancers are often created from , a process with comes with a great many mutations (changes in the gene code) in genes that are part of the unstable, frequent cell division and multiplication seen in cancer. By starting with of JMML patients with inherited PTPN11 mutations, researchers were able to create JMML with only these mutations, screening out the "genetic noise" that can obscure disease mechanisms.

"Our results provide further evidence that the severity of this form of leukemia arises from the degree of changes in the gene PTPN11, altering the protein it codes for, SHP-2, and biologic pathways related to it," said Dr. Gelb. "These proteins promise to become a focus of future drug design efforts."

Along with Dr. Gelb, study authors were Sonia Mulero-Navarro, Nelson Rodriguez, and Dhandapany Perundurai of The Mindich Child Health and Development Institute, along with Ana Sevilla, Dung-Fang Lee, Sunita D'Souza, Jie Su, Christoph Schaniel, Kateri Moore and Ihor Lemischka of The Black Family Stem Cell Institute and Department of Developmental and Regenerative Biology, Icahn School of Medicine. Also making important contributions were authors Ninette Cohen, Alessia Baccarini, Brian Brown, Lisa Edelmann, and Sawsan Bahieg in the Department of Genetics and Genomic Sciences, along with Perundurai Ge Yongchao in the Department of Neurology. Some of the above authors are also faculty in the departments of Pharmacology and Systems Therapeutics and Pediatrics.

Explore further: Stem cell transplantation for children with rare form of leukemia improves outcomes

Related Stories

Stem cell transplantation for children with rare form of leukemia improves outcomes

July 23, 2015
Researchers in the Division of Hematology, Oncology and Blood & Marrow Transplantation at Children's Hospital Los Angeles have shown greatly improved outcomes in using stem cell transplantation to treat patients with a serious ...

Stem cell disease model clarifies bone cancer trigger

April 9, 2015
Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers, ...

Reprogramming patients' cells offers powerful new tool for studying, treating blood diseases

July 30, 2013
First produced only in the past decade, human induced pluripotent stem cells (iPSCs) are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with ...

Microenvironment of hematopoietic stem cells can be a target for myeloproliferative disorders

June 22, 2014
The protective microenvironment of the hematopoietic stem cell niche, which produces cells of the blood and the immune system, also protects against myeloproliferative neoplasia.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.